Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

163.22 -0.69 (-0.42%)
Streaming Delayed Price Updated: 1:20 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
55 56 Next >
News headline image
AI 2.0 is Here: How to Invest in a Generational Opportunity
AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it. 
Via MarketBeat
Topics Artificial Intelligence Supply Chain
News headline image
Could This Biosimilar Drug Be Novartis' Next Blockbuster? ↗
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
News headline image
8 Pharma Stocks Affected by New Drug Price Negotiation Rules ↗
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
News headline image
Price Over Earnings Overview: Novartis ↗
 
Via Benzinga
News headline image
Peering Into Novartis's Recent Short Interest ↗
 
Via Benzinga
News headline image
2 Excellent Stocks to Buy and Hold Forever ↗
These companies have solid long-term potential. 
Via The Motley Fool
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
These drugmakers are among the most dominant in the world. 
Via The Motley Fool
News headline image
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
News headline image
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet ↗
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
News headline image
Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck
Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027 
Via SBWire
News headline image
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks? ↗
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
News headline image
Transdermal Drug Patches Market to See Huge Growth : Novartis, Mylan, Accrux
Stay up-to-date with Transdermal Drug Patches Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts ↗
To gain an edge, this is what you need to know today. 
Via Benzinga
News headline image
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle ↗
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
News headline image
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts ↗
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
News headline image
3 AI Stocks With the Potential to Transform Your Financial Future ↗
Are you looking to invest in AI stocks? Here are three picks with the potential to transform your financial future. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
3 Emerging Market Stocks to Buy in August ↗
These three emerging market stocks to buy in August will have very strong, positive catalysts going forward. 
Via InvestorPlace
News headline image
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest ↗
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the... 
Via Benzinga
News headline image
Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz ↗
CVS Health Corp (NYSE: CVS) has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar  
Via Benzinga
News headline image
Could This Medicine Be the Next Winner for Novartis? ↗
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
News headline image
Gold Rush In Weight Loss Industry Impacts Retailers With Pharmacy Businesses ↗
Retailers with pharmacy businesses, including major players like Walmart Inc (NYSE: WMT), Kroger Company (NYSE: KR), and Rite Aid Corp (NYSE: 
Via Benzinga
News headline image
A Comprehensive Study Exploring Breast Cancer Drugs Market : Key Players- Sanofi, Novartis, Lilly ↗
The Global Breast Cancer Drugs Market offers energetic visions to conclude market size, opportunities, growth pattern, and competitive surroundings. The research is derived through primary and... 
Via SBWire
News headline image
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms ↗
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected. 
Via Investor's Business Daily
News headline image
SpaceX On Par With Intel, Disney; US Weight Loss Drugs Pricier; Moderna, Pfizer's Shot Effective Against New Variant: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients ↗
Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible  
Via Benzinga
News headline image
Novartis' Generic Business Spinoff: Plans Sandoz Spin-Off In Early October, Proposes Share Distribution ↗
Novartis AG (NYSE: NVS)  
Via Benzinga
News headline image
COPD & Asthma Devices Market to Witness Remarkable Growth by 2029 : Pfizer, GSK, Novartis, Merck ↗
Stay up to date with COPD & Asthma Devices Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Addiction Treatment Market May See New Emerging Trends: Novartis, Pfizer, Sanofi ↗
Pune, Maharashtra -- (SBWIRE) -- 08/17/2023 -- 2023-2031 Report on Global Addiction Treatment Market by Player, Region, Type, Application and Sales Channel is the latest research study released by HTF... 
Via SBWire
News headline image
Essential Thrombocythemia Market Projected to Show Strong Growth : Pharmaessentia, Bristol Myers Squibb, Shire
Get an extensive Essential Thrombocythemia Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
News headline image
3 Unstoppable Dividend Stocks to Buy Right Now ↗
These stocks' dividends are more dependable than most. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.